Under half of new cancer drugs increase survival by three months, study finds
BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j30 (Published 04 January 2017) Cite this as: BMJ 2017;356:j30- Susan Mayor
- London
New cancer drugs vary greatly in improving overall survival and the quality of life they achieve when compared with previous treatments, says a study systematically evaluating health technology assessments of new anticancer agents approved from 2003 to 2013.1
“There are growing questions about the value gained from spending on what seem to be ever more expensive cancer medicines,” said the researchers, led by Elias Mossialos, of the London School of Economics and Political Science in London, UK.
The use of many different outcome measures …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.